This article is a correction to:
Experimental validation of immunogenic SARS-CoV-2 T cell epitopes identified by artificial intelligence
Lorenzo Federico1,2*
Brandon Malone3
Simen Tennøe3Viktoriia Chaban1,2Julie Røkke Osen1,2
Murat Gainullin1,2Eva Smorodina1,4
Hassen Kared1,2Rahmad Akbar1,4
Victor Greiff1,4Richard Stratford3
Trevor Clancy3
Ludvig Andre Munthe1,2*- 1Department of Immunology, Oslo University Hospital, Oslo, Norway
- 2KG Jebsen Centre for B cell Malignancies, Institute of Clinical Medicine, University of Oslo, Oslo, Norway
- 3NEC OncoImmunity AS, Oslo, Norway
- 4Institute of Clinical Medicine, Oslo University Hospital, Oslo, Norway
A Corrigendum on
Experimental validation of immunogenic SARS-CoV-2 T cell epitopes identified by artificial intelligence
by Federico L, Malone B, Tennøe S, Chaban V, Osen JR, Gainullin M, Smorodina E, Kared H, Akbar R, Greiff V, Stratford R, Clancy T and Munthe LA (2023) Front. Immunol. 14:1265044. doi: 10.3389/fimmu.2023.1265044
Text correction
In the published article, there were two errors: The “Material and methods” section preceded the “Introduction” section, and there was an inaccuracy in the wording of a sentence in the “Reagents” sub-section of “Material and methods”.
The “Introduction” now precedes the “Material and methods”, and a correction has been made to a sentence in “Materials and methods”, sub-section “Reagents”.
This sentence previously stated:
“Peptides were synthesized by GenScript (Piscataway, NJ, USA) at a purity ≥85%, and used at a final concentration of 1.5mg/mL each.”
The corrected sentence appears below:
“Peptides were synthesized by GenScript (Piscataway, NJ, USA) at a purity ≥85% and stored at a final concentration of 1.5mg/mL.”
The authors apologize for these errors and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Keywords: T cell, COVID-19, CD8+ lymphocytes, CD4+ lymphocytes, vaccine, SARS-CoV-2, artificial intelligence, antigen (Ag)
Citation: Federico L, Malone B, Tennøe S, Chaban V, Osen JR, Gainullin M, Smorodina E, Kared H, Akbar R, Greiff V, Stratford R, Clancy T and Munthe LA (2024) Corrigendum: Experimental validation of immunogenic SARS-CoV-2 T cell epitopes identified by artificial intelligence. Front. Immunol. 15:1377041. doi: 10.3389/fimmu.2024.1377041
Received: 26 January 2024; Accepted: 05 February 2024;
Published: 21 February 2024.
Edited and Reviewed by:
Elke Bergmann-Leitner, Walter Reed Army Institute of Research, United StatesCopyright © 2024 Federico, Malone, Tennøe, Chaban, Osen, Gainullin, Smorodina, Kared, Akbar, Greiff, Stratford, Clancy and Munthe. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Lorenzo Federico, lorenzo.federico@medisin.uio.no; Ludvig Andre Munthe, l.a.munthe@medisin.uio.no